Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug

The New York Times - Business:

The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.

Author: Pam Belluck

This post first appeared in The New York Times - Business. Read the original article.